Comparative Pharmacology
Head-to-head clinical analysis: DUAKLIR PRESSAIR versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAKLIR PRESSAIR versus GLYCORT.
DUAKLIR PRESSAIR vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dual bronchodilator combining a long-acting muscarinic antagonist (aclidinium) and a long-acting beta2-agonist (formoterol). Aclidinium inhibits acetylcholine at M3 receptors, reducing bronchoconstriction; formoterol stimulates beta2-adrenergic receptors, relaxing airway smooth muscle.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
1 inhalation (aclidinium 400 mcg / formoterol 12 mcg) twice daily.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Terminal half-life 5.0–6.5 hours (aclidinium); steady-state reached within 2 days; no accumulation at therapeutic doses
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Renal (55% as unchanged aclidinium; 20% as metabolites); biliary/fecal (33% as metabolites and parent)
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Anticholinergic